LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: February 2, 2001
Last updated: December 18, 2013
Last verified: January 2007

RATIONALE: LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced pancreatic, esophageal, stomach, colon or rectal cancer.

PURPOSE: Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced pancreatic, esophageal, stomach, colon, or rectal cancer.

Condition Intervention Phase
Colorectal Cancer
Esophageal Cancer
Gastric Cancer
Pancreatic Cancer
Biological: LMB-9 immunotoxin
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 50
Study Start Date: April 2001
Detailed Description:


  • Determine the toxicity of LMB-9 immunotoxin in patients with advanced adenocarcinoma of the colon, rectum, pancreas, esophagus, or stomach with overexpression of the Lewis-Y antigen.
  • Determine the maximum tolerated dose of this drug in these patients.
  • Determine the clinical response of patients treated with this drug.
  • Determine the pharmacokinetics of this drug in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive LMB-9 immunotoxin IV continuously on days 1-5. Patients with stable or responding disease after completion of the first course receive additional courses every 4-5 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 3 weeks and then every 2 months thereafter.

PROJECTED ACCRUAL: A total of 40-50 patients will be accrued for this study within 1-2 years.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed advanced adenocarcinoma of the colon, rectum, pancreas, esophagus, or stomach that is refractory to standard treatment
  • Overexpression of the Lewis-Y antigen
  • Measurable or evaluable disease
  • No CNS metastasis
  • Metastatic liver disease from primary tumor allowed



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • At least 3 months


  • Platelet count greater than 100,000/mm^3
  • Absolute granulocyte count greater than 1,200/mm^3


  • Bilirubin normal
  • SGOT and SGPT no greater than 1.5 times upper limit of normal
  • Hepatitis B or C antigen negative
  • No liver disease (e.g., alcohol liver disease)
  • Albumin at least 3.0 g/dL


  • Creatinine no greater than 1.4 mg/dL
  • Creatinine clearance at least 60 mL/min
  • Proteinuria no greater than 1 g/24 hours (grade II toxicity-like)


  • No prior coronary artery disease
  • No New York Heart Association class II, III, or IV congestive heart failure
  • No arrhythmia requiring treatment


  • FEV_1 and FVC greater than 65% predicted


  • No other concurrent malignancy
  • No active peptic ulcer disease
  • No known allergy to omeprazole
  • No known seizure disorder
  • No concurrent medical or psychiatric condition that would preclude study participation
  • No contraindication to pressor therapy
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

Endocrine therapy:

  • At least 3 weeks since prior hormonal therapy


  • At least 3 weeks since prior radiotherapy and recovered


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00010270

Universitaetsklinikum Freiburg
Freiburg, Germany, D-79106
Sponsors and Collaborators
University Hospital Freiburg
National Cancer Institute (NCI)
Study Chair: Peter Hafkemeyer, MD Kreiskrankenhaus Emmendingen
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00010270     History of Changes
Other Study ID Numbers: CDR0000068462, UFMC-431, UFMC-IND-7697, UFMC-NSC-691236, NCI-431, EU-20120
Study First Received: February 2, 2001
Last Updated: December 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV colon cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
adenocarcinoma of the colon
stage III pancreatic cancer
stage II pancreatic cancer
recurrent pancreatic cancer
adenocarcinoma of the pancreas
stage IV gastric cancer
adenocarcinoma of the stomach
recurrent gastric cancer
adenocarcinoma of the esophagus
stage IV esophageal cancer
stage III esophageal cancer
recurrent esophageal cancer
stage II esophageal cancer
adenocarcinoma of the rectum
stage III colon cancer
stage III rectal cancer
stage III gastric cancer
stage IV pancreatic cancer

Additional relevant MeSH terms:
Esophageal Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Pancreatic Diseases
Stomach Diseases
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 09, 2015